December 2005
Worldwide Biotech;Dec2005, Vol. 17 Issue 12, p6
Trade Publication
Reports on the launching of the expanded access program of Tibotec Pharmaceuticals Ltd. for its investigational protease inhibitor TMC114, in the U.S. Information on TMC114; Overview of the expanded access program; Background of the company.


Related Articles

  • Cost inhibitor.  // Echo Magazine;7/13/2006, Vol. 17 Issue 22, p49 

    Reports on the criticism of the AIDS Healthcare Foundation (AHF) against the pricing of protease inhibitors Prezista manufactured by Tibotec. Expectations of AHF on the cost of the drug; Overview of the drug's mechanism of action; Comment from Michael Weinstein, president of AHF, on the...

  • Darunavir/ritonavir - a POWERful option for HIV. McWilliams, Pauline // PharmacoEconomics & Outcomes News;2/19/2011, Issue 622, p3 

    The article discusses studies on the cost effectiveness of darunavir-boosted by low-dose ritonavir (DRV/r) as a treatment for HIV infections and published in the "PharmacoEconomics" journal. Developed by Tibotec Pharmaceuticals, darunavir was launched in the U.S. for the treatment of HIV...

  • AASLD Roundup.  // BioWorld Today;11/4/2008, Vol. 19 Issue 215, p5 

    The article reports that Tibotec BVBA presented interim data from a Phase IIa hepatitis C virus (HCV) trial of protease inhibitor TMC435 at the annual meeting of the American Association for the Study of Liver Disease (AASLD) in 2008. The study found that 89 percent of patients treated with the...

  • EASL Roundup.  // BioWorld Today;4/27/2009, Vol. 20 Issue 79, p3 

    The article reports on the data presented by Medivir AB of Stockholm, Sweden from a Phase IIa trial of TMC435, a protease inhibitor being developed with Tibotec BVBA. The data showed the viral load reductions in treatment-naïve, genotype 1 hepatitis C virus patients receiving TMC435 plus...

  • Ontario Okays Prezista.  // Guide;Jul2007, Vol. 27 Issue 7, p89 

    The article reports on the approval of Prezista, a protease inhibitor made by Tibotec, by Health Canada. The Drug has been added to the Ontario Drug Benefit Formulary. The cost of Prezista will also be covered under the Ontario Drug Benefit Program. The Common Drug Review has recommended the...

  • New HIV Treatment.  // FDA Consumer;Sep/Oct2006, Vol. 40 Issue 5, p7 

    The article reports that the U.S. Food and Drug Administration approved the protease inhibitor Prezista, or darunavir, for the treatment of HIV infection in adults. Prezista is approved to be used with a low dose of ritonavir and with other active anti-HIV agents. Studies showed that the...

  • Tibotec: safety warning highlights limitation of protease inhibitors.  // PharmaWatch: Monthly Review;Apr2008, Vol. 7 Issue 4, p23 

    The article reports on the safety warning issued by the U.S. Food and Drug Administration (FDA) and Tibotec for the company's protease inhibitor (PI) Prezista. The fifteen cases of liver problems and several deaths that occurred in Prezista patients during clinical trials triggered the company...

  • Tibotec warns of hepatotoxicity with darunavir.  // Reactions Weekly;5/24/2008, Issue 1203, p2 

    The article reports on the warning against the hepatotoxicity with darunavir. Health Canada supported the public communication and Dear Health Care Professional letter issued by Tibotec regarding the potential effects of using Prezista, an HIV protease inhibitor darunavir. Tibotec advised...

  • TIBOTEC GETS AIDS. Armstrong, Walter // Pharmaceutical Executive;Aug2007, Vol. 27 Issue 8, p48 

    The article offers information about Tibotec, a biotech born in Belgium in 1994 and was bought by Johnson & Johnson in 2002 for $320 million. The company is responsible for the releases of drugs Prezista, a protease inhibitor, and etravarine and rilpivirine, two new non-nucleosides. Its latest...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics